Published Year: 2023
Global EV(Extracellular vesicles)-Based Liquid Biopsy Market - A Global and Regional Analysis: Focus
The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion Criteria
2.1 Key Questions Answered in the Report:
3.1 EV-Based Liquid Biopsy Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4.1 Market Introduction
4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
4.3 Current Market Size and Growth Potential, $Million, 2022-2032
4.4 COVID-19 Impact on EV-based Liquid Biopsy Market
4.4.1 Impact on Operations
4.4.2 COVID-19 Impact: Current Scenario of the Market
5.1 Overview
5.1.1 Evs Introduction
5.2 Isolation Methods
5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
5.2.1.1 Differential Ultracentrifugation
5.2.1.2 Density Gradient Centrifugation
5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
5.2.1.4 Isopycnic Centrifugation
5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
5.2.2.1 Ultrafiltration
5.2.2.2 Sequential Filtration
5.2.2.3 Size Exclusion Chromatography (SEC)
5.2.2.4 Flow Field-Flow Fractionation (FFFF)
5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.3.2 Magneto-Immunoprecipitation
5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
5.2.4.1 Polyethylene Glycol (PEG) Precipitation
5.2.4.2 Lectin Induced Agglutination
5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
5.2.6 EV Isolation Techniques Utilizing Commercial Kits
5.2.7 Advantages and Disadvantages of the EV Isolation Methods
5.2.8 Novel Approaches for Exosome Isolation
5.3 Analysis Methods
5.3.1 Advantages and Disadvantages of Analysis Methods for Evs
6.1 Overview
6.2 Legal Requirements in the U.S.
6.3 Legal Requirements and Frameworks in Europe
6.4 Legal Requirements and Frameworks in Asia-Pacific
6.5 Reimbursement Scenario
7.1 Overview
7.2 Impact Analysis
7.3 Market Drivers
7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
7.3.2 Amplified Funding and Dedicated Research Efforts
7.3.3 Rising Prevalence of Cancers
7.4 Market Restraints
7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
7.5 Market Opportunities
7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
7.5.2 Development of New EV-Based Biomarkers
7.5.3 Approved Products in the Market
8.1 Overview
8.2 Europe
8.2.1 Germany
8.2.2 U.K.
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest-of-Europe
9.1 Company Overview
9.1.1 Abcam plc
9.1.1.1 Company Overview
9.1.1.2 Role of Abcam plc in the EV-Based Liquid Biopsy Market
9.1.1.3 Major Products: Key Specifications
9.1.1.4 Key Competitors
9.1.1.5 Analyst Perspective
9.1.2 Qiagen N.V.
9.1.2.1 Company Overview
9.1.2.2 Role of Qiagen N.V. in the EV-Based Liquid Biopsy Market
9.1.2.3 Major Products: Key Specifications
9.1.2.4 Key Competitors
9.1.2.5 Analyst Perspective
9.1.3 Malvern Panalytical Ltd
9.1.3.1 Company Overview
9.1.3.2 Role of Malvern Panalytical Ltd in the EV-Based Liquid Biopsy Market
9.1.3.3 Major Products: Key Specifications
9.1.3.4 Key Competitors
9.1.3.5 Analyst Perspective
9.1.4 Lonza Group AG
9.1.4.1 Company Overview
9.1.4.2 Role of Lonza Group AG in the EV-Based Liquid Biopsy Market
9.1.4.3 Major Products: Key Specifications
9.1.4.4 Key Competitors
9.1.4.5 Analyst Perspective
Table 1: Current and Future State of EV-Based Liquid Biopsy in Industries
Table 2: Example of Few Commercial Kits Available for EV Isolation
Table 3: Advantages and Disadvantages of the EV Isolation Methods
Table 4: Emerging Methods for the Isolation of Exosomes
Table 5: Advantages and Disadvantages of Analysis Methods for Evs
Table 6: Legal Requirements in the U.S.
Table 7: Legal Landscape for EV-Based Liquid Biopsies in Europe
Table 8: Size and Densities of Evs and Various Lipoproteins
Table 9: Technological Advancements in EV-Based Liquid Biopsy
Figure 1: EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
Figure 2: EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
Figure 3: EV-Based Liquid Biopsy Market (by Region), 2022
Figure 4: EV-Based Liquid Biopsy Market Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 9: Subtypes of Evs
Figure 10: Methods of EV-Isolation from Biofluids
Figure 11: Workflow of Differential Ultracentrifugation for Exosome Isolation
Figure 12: Methods of EV-Analysis
Figure 13: EV-Based Liquid Biopsy Market – Market Dynamics
Figure 14: Structure of Evs Enveloped by Protective Lipid Membrane
Figure 15: Number of Research Publications on Exosomes, 2015-2021
Figure 16: Share of New Cancer Cases, 2020
Figure 17: Number of Cancer Cases, 2020
Figure 18: Currently Investigated Circulating Biomarkers Associated with Evs
Figure 19: EV-Based Liquid Biopsy Market Snapshot (by Region)
Figure 20: EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
Figure 21: Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 22: Europe: Market Dynamics
Figure 23: Europe EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
Figure 24: Germany EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 25: U.K. EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 26: France EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 27: Italy EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 28: Spain EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 29: Rest-of-Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
Figure 30: Total Number of Companies Profiled
Figure 31: Abcam plc: Product Portfolio
Figure 32: Qiagen N.V.: Product Portfolio
Figure 33: Malvern Panalytical Ltd: Product Portfolio
Figure 34: Lonza Group AG: Product Portfolio
Europe EV-Based Liquid Biopsy Market Report Coverage
|
Europe EV-Based Liquid Biopsy Market |
|||
|
Base Year |
2022 |
Market Size in 2022 |
$18.88 Million |
|
Forecast Period |
2023-2032 |
Value Projection and Estimation by 2032 |
$115.34 Million |
|
CAGR During Forecast Period |
20.30% |
||
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
• Abcam plc
• Qiagen N.V.
• Malvern Panalytical Ltd
• Lonza Group AG
How can this report add value to an organization?
Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.
Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.
Introduction to Europe EV (Extracellular vesicles)-Based Liquid Biopsy Market
The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032, witnessing a CAGR of 20.30% during the forecast period 2023-2032. The Europe EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.
Market introduction
The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease. The field of healthcare diagnostics has been revolutionized by its non-invasiveness, real-time monitoring capabilities, and potential for early disease diagnosis. EV-based liquid biopsy has improved patient outcomes, decreased expenses associated with healthcare, and provided a less intrusive and more accessible means of monitoring and diagnosing diseases, including cancer. Furthermore, the market expansion is anticipated to be aided by the entry of many established companies, including Bio-Techne Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.
In addition, the market expansion for EV-based liquid biopsies has created economic opportunities, prompted industrial participants to collaborate with academic institutions, and sparked research and development efforts.
Market Segmentation
Segmentation 1: by Country
• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe"
Europe EV-Based Liquid Biopsy Market
Analysis and Forecast, 2023-2032
Some Faq's
Frequently Asked Questions
Cancer cells secrete extracellular vesicles (EVs), which are a special kind of communication between cells that can enhance invasive and metastatic activity, support cell proliferation and survival, and assist build the tumor microenvironment.
A biopsy involves the removal and examination of a tissue sample, while a liquid biopsy involves the analysis of genetic material shed by tumors into bodily fluids. Biopsies are more invasive but provide a detailed examination of tissue structure, while liquid biopsies are less invasive and offer a means of analyzing tumor-specific genetic material in a non-solid sample.
EVs have become important intercellular communication mediators in cancer. Since tumor-EVs in blood or other bodily fluids have the malignant characteristics of the cells that gave rise to them, these cells are a prime option for use as biomarkers in liquid biopsies to identify, evaluate, and track the progression of tumors.
• Companies that manufacture and commercialize consumables and equipment related to EV-based liquid biopsy.
• Any new entrant that wants to know where the opportunities lie in the EV-based liquid biopsy market.
• Any established player that wants to expand its product portfolio or business in new geographies.
Similar Product
You may also like